-
公开(公告)号:US5763420A
公开(公告)日:1998-06-09
申请号:US450930
申请日:1995-05-25
申请人: Ryoichi Osawa , Isao Suda , Masaaki Numata , Mamoru Sugimoto , Kenkichi Tomita , Nobuyuki Kibushi , Takayuki Ishii , Naokazu Sugiyama , Makiko Kasano , Tae Yasunaga , Makoto Tanaka , Tomoya Ogawa , Mariko Ishii
发明人: Ryoichi Osawa , Isao Suda , Masaaki Numata , Mamoru Sugimoto , Kenkichi Tomita , Nobuyuki Kibushi , Takayuki Ishii , Naokazu Sugiyama , Makiko Kasano , Tae Yasunaga , Makoto Tanaka , Tomoya Ogawa , Mariko Ishii
IPC分类号: C12P19/04 , A61K31/70 , A61K31/715 , A61P7/02 , A61P13/02 , A61P15/00 , A61P37/08 , C07H13/04 , C12R1/01 , A61K31/735
CPC分类号: A61K31/715 , A61K31/70 , A61K31/7012 , A61K31/7016 , A61K31/702 , C07H13/04 , Y10S514/825 , Y10S514/885
摘要: An anti-inflammatory drug comprising as the effective component at least one compound selected from the group consisting of colominic acid, partial hydrolysis products of colominic acid and pharmaceutically acceptable salts, thereof. The drug is used as a drug for renal diseases, a drug for hepatitis, an immunomodulator and a drug for inhibiting the chemotaxis of neutrophil.
摘要翻译: 一种抗炎药,其包含选自科洛芬酸,聚洛米酸的部分水解产物和其药学上可接受的盐的至少一种化合物作为有效成分。 该药用作肾脏疾病的药物,用于肝炎的药物,免疫调节剂和抑制嗜中性粒细胞趋化性的药物。
-
公开(公告)号:US5668115A
公开(公告)日:1997-09-16
申请号:US450699
申请日:1995-05-25
申请人: Ryoichi Osawa , Isao Suda , Masaaki Numata , Mamoru Sugimoto , Kenkichi Tomita , Nobuyuki Kibushi , Takayuki Ishii , Naokazu Sugiyama , Makiko Kasano , Tae Yasunaga , Makoto Tanaka , Tomoya Ogawa , Mariko Ishii
发明人: Ryoichi Osawa , Isao Suda , Masaaki Numata , Mamoru Sugimoto , Kenkichi Tomita , Nobuyuki Kibushi , Takayuki Ishii , Naokazu Sugiyama , Makiko Kasano , Tae Yasunaga , Makoto Tanaka , Tomoya Ogawa , Mariko Ishii
IPC分类号: C12P19/04 , A61K31/70 , A61K31/715 , A61P7/02 , A61P13/02 , A61P15/00 , A61P37/08 , C07H13/04 , C12R1/01
CPC分类号: A61K31/715 , A61K31/70 , A61K31/7012 , A61K31/7016 , A61K31/702 , C07H13/04 , Y10S514/825 , Y10S514/885
摘要: An anti-inflammatory drug comprising as the effective component at least one compound selected from the group consisting of colominic acid, partial hydrolysis products of colominic acid and pharmaceutically acceptable salts thereof. The drug is used as a drug for renal diseases, a drug for hepatitis, an immunomodulator and a drug for inhibiting the chemotaxis of neutrophil.
摘要翻译: 一种抗炎药,其包含选自科洛芬酸,聚洛米酸的部分水解产物和其药学上可接受的盐中的至少一种化合物作为有效成分。 该药用作肾脏疾病的药物,用于肝炎的药物,免疫调节剂和抑制嗜中性粒细胞趋化性的药物。
-
公开(公告)号:US5516764A
公开(公告)日:1996-05-14
申请号:US219236
申请日:1994-03-28
申请人: Ryoichi Osawa , Isao Suda , Masaaki Numata , Mamoru Sugimoto , Kenkichi Tomita , Nobuyuki Kibushi , Takayuki Ishii , Naokazu Sugiyama , Makiko Kasano , Tae Yasunaga , Makoto Tanaka , Tomoya Ogawa , Mariko Ishii
发明人: Ryoichi Osawa , Isao Suda , Masaaki Numata , Mamoru Sugimoto , Kenkichi Tomita , Nobuyuki Kibushi , Takayuki Ishii , Naokazu Sugiyama , Makiko Kasano , Tae Yasunaga , Makoto Tanaka , Tomoya Ogawa , Mariko Ishii
IPC分类号: C12P19/04 , A61K31/70 , A61K31/715 , A61P7/02 , A61P13/02 , A61P15/00 , A61P37/08 , C07H13/04 , C12R1/01 , A01N43/04 , C07H1/00
CPC分类号: A61K31/715 , A61K31/70 , A61K31/7012 , A61K31/7016 , A61K31/702 , C07H13/04 , Y10S514/825 , Y10S514/885
摘要: An anti-inflammatory drug comprising as the effective component at least one compound selected from the group consisting of colominic acid, partial hydrolysis products of colominic acid and pharmaceutically acceptable salts thereof. The drug is used as a drug for renal diseases, a drug for hepatitis, an immunomodulator and a drug for inhibiting the chemotaxis of neutrophil.
摘要翻译: 一种抗炎药,其包含选自科洛芬酸,聚洛米酸的部分水解产物和其药学上可接受的盐中的至少一种化合物作为有效成分。 该药用作肾脏疾病的药物,用于肝炎的药物,免疫调节剂和抑制嗜中性粒细胞趋化性的药物。
-
公开(公告)号:US5231177A
公开(公告)日:1993-07-27
申请号:US488860
申请日:1990-03-05
申请人: Kinichi Saito , Hideo Mizu , Naokazu Sugiyama , Shikoh Minagawa , Motoaki Goto , Kenji Abiko
发明人: Kinichi Saito , Hideo Mizu , Naokazu Sugiyama , Shikoh Minagawa , Motoaki Goto , Kenji Abiko
IPC分类号: C07H13/06 , A61K31/70 , A61K31/7024 , A61P11/10 , C07H13/04
CPC分类号: C07H13/04
摘要: Sodium N-acetylneuraminate trihydrate herein provided is represented by the following formula: ##STR1## The sodium N-acetylneuraminate trihydrate can be prepared, for instance, according to a method which comprises the steps of: dissolving sodium N-acetylneuraminate in water or in a mixture of water and an organic solvent; allowing the resulting solution to stand; precipitating and separating the resulting crystals of sodium N-acetylneuraminate.trihydrate; and then drying the separated crystals. The sodium N-acetylneuraminate trihydrate has very low hygroscopicity and hence can be handled without any difficulty in the form of powder.
-
-
-